Is there a place for screening in ovarian cancer?

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 82, Issue 2, 1999, Pages 155-157

  MacDonald, N D ^a   Jacobs, I J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER SCREENING; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; ULTRASOUND;

EID: 0033042325     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00219-X     Document Type: Conference Paper

References (16)

1. Office of Population Censuses and Surveys (OPCS). Cancer Statistics: Registrations 1991. MB1 no 24. London: HMSO, 1997.
2. Nguyen N.H., Averette H.E., Hoskins W., Sevin B.U., Penalver M., Steren A. National Survey of Ovarian Carcinoma VI. Critical assessment of current International Federation of Obstetrics and Gynaecology staging system. Cancer. 72:1993;3007-3011.
3. Campbell S., Bhan V., Royston P., Whitehead M.I., Collins W.P. Transabdominal ultrasound screening for ovarian cancer. Br Med J. 299:1989;1363-1367.
4. Van Nagell J.R., Gallion H.D., Pavlik E.J., DePriest P.D. Ovarian cancer screening. Cancer. 76:1995;2086-2091.
5. Kurjak A., Schulman H., Sosic A., Zalud I., Shalan H. Transvaginal ultrasound, color flow, and Doppler waveform of the postmenopausal adnexal mass. Obstet Gynecol. 80:1992;917-921.
6. Bast R.C. Jr., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 68:1981;1331-1337.
7. Jacobs I., Bast R.C. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 41(1):1989;1-12.
8. Einhorn N., Sjovall K., Knapp R.C., Hall P., Scully R.E., Bast R.C.J.R.et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 80:1992;14-18.
9. Jacobs I., Davies A.P., Bridges J., Stabile I., Fay T., Lower A.et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br Med J. 306:1993;1030-1034.
10. Skates S.J., Xu F.J., Yu Y.H., Sjovall K., Einhorn N., Chang Y.et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumour markers. Cancer. 76:1995;2004-2010.
11. Wolfe C.D., Raju K.S. The attitudes of women and feasibility of screening for ovarian and endometrial cancers in inner city practices. Eur J Obstet Gynecol Reprod Biol. 56:1994;117-120.
12. Guy R.L., King E., Ayers A.B. The role of transvaginal ultrasound in the assessment of the female pelvis. Clin Radiol. 39:1988;669-672.
13. Wardle F.J., Collins W., Pernet A L., Whitehead M.I., Bourne T.H., Campbell S. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst. 85:1993;653-657.
14. Urban N., Drescher C., Etzioni R., Colby C. Use of a stochastic model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials. 18(3):1997;251-270.
15. Xu F.J., Yu Y.A., Daly L.et al. The OVX1 radioimmunoassay complements CA125 for predicting the presence of residual ovarian carcinoma at second look surgical surveillance procedures. J Clin Oncol. 11:1993;1506-1510.
16. Xu F.J., Ramakrishnan S., Daly L.et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol. 165(5 Pt 1):1991;1356-1362.